Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-25T16:40:01.692Z Has data issue: false hasContentIssue false
  • English
  • Français

Commentary

Response to Professor Kerwin

Published online by Cambridge University Press:  02 January 2018

T. R. E. Barnes
T. R. E. Barnes*
Affiliation:
Department of Psychiatry, Charing Cross and Westminster Medical School, St Dunstan's Road, London W6 8RP
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Original Papers
Information
Psychiatric Bulletin , Volume 20 , Issue 1 , January 1996 , pp. 26 - 29
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 1996

References

Aitchison, K. J. & Kerwin, R. W. (1995) The cost and benefit of clozapine therapy in the UK (Abstract). Schizophrenia Research, 15, 141.CrossRefGoogle Scholar
Baldessarini, R. J., Cohen, B. M. & Teicher, M. H. (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry, 46, 79–91.CrossRefGoogle Scholar
Barnes, T. R. E. & Curson, D. A. (1994) Long-acting depot antipsychotics: a risk-benefit assessment. Drug Safety, 10, 464–479.CrossRefGoogle Scholar
Barnes, T. R. E. & Curson, D. A. & Edwards, J. G. (1993) The side-effects of antipsychotic drugs. I. Neuropsychiatric effects. In Antipsychotic Drugs and Their Side-Effects (ed. T. R. E. Barnes), pp. 213–247. London: Academic Press.Google Scholar
Barnes, T. R. E. & Curson, D. A. Milavic, G., Curson, D. A., et al (1983) Use of the Social Behaviour Assessment Schedule (SBAS) in a trial of maintenance antipsychotic therapy in schizophrenic outpatients: pimozide versus fluphenazine. Social Psychiatry, 18, 193–199.CrossRefGoogle Scholar
Bebbington, P. E. (1995) The content and context of compliance. International Clinical Psychopharmacology, 9 (Suppl. 5), 41–50.CrossRefGoogle ScholarPubMed
Bosanquet, N. & Zajdler, A. (1993) Psychopharmacology and the ethics of resource allocation. British Journal of Psychiatry, 162, 29–32.CrossRefGoogle Scholar
Bredbacka, P. E., Paukkala, E., Kinnunen, E., et al (1993) Can severe cardiorespiratory dysregulation induced by clozapine monotherapy be predicted? International Clinical Psychopharmacology, 8, 205–206.Google Scholar
Carpenter, W. T., Conley, R. R., Buchanan, R. W., et al (1995) Patient response and resource management: another view of clozapine treatment of schizophrenia. American Journal of Psychiatry, 152, 827–832.Google ScholarPubMed
Davies, L. M. & Drummond, M. F. (1993) Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. British Journal of Psychiatry, 162, 38–42.CrossRefGoogle ScholarPubMed
Edwards, J. G. & Barnes, T. R. E. (1993) The side-effects of antipsychotic drugs. II. Effects on other physiological systems. In Antipsychotic Drugs and Their Side-Effects. (ed. T. R. E. Barnes), pp. 249–275. London: Academic Press.Google Scholar
Fitton, A. & Benfield, P. (1993) Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. PharmacoEconomics, 4, 131–156.CrossRefGoogle ScholarPubMed
Grohmann, R., Ruther, E., Sassim, N., et al (1989) Adverse effects of clozapine. Psychopharmacology, 99, S101–S104.Google Scholar
Healy, D. (1993) Psychopharmacology and the ethics of resource allocation. British Journal of Psychiatry, 162, 23–29.CrossRefGoogle ScholarPubMed
Hirsch, S. R. & Barnes, T. R. E. (1994) Clinical use of high-dose neuroleptics. British Journal of Psychiatry, 164, 94–96.Google Scholar
Hirsch, S. R. & Barnes, T. R. E. & Puri, B. K. (1993) Clozapine: progress in treating refractory schizophrenia (Editorial). British Medical Journal 306, 1427–1428.Google Scholar
Jusic, N. & Lader, M. (1994) Post-mortem antipsychotic drug concentrations and unexplained deaths. British Journal of Psychiatry, 165, 787–791.Google Scholar
Kane, J. M. (1994) Risperidone (Editorial). American Journal of Psychiatry, 151, 802–803.Google Scholar
Keck, P. E., Cohen, B. M., Baldessarini, R. J., et al (1989) Time course of antipsychotic effects of neuroleptic drugs. American Journal of Psychiatry, 146, 1289–1292.Google Scholar
Kinon, B. J., Kane, J. M., Johns, C., et al (1993) Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacology Bulletin, 29, 309–314.Google ScholarPubMed
Lamberti, J. S., Bellnier, T. & Schwarzkopf, S. B. (1992) Weight gain among schizophrenic patients treated with clozapine. American Journal of Psychiatry, 149, 689–690.Google Scholar
Matheson, L. A., Cook, H. M., McKenna, P., et al (1994) Value for money care for patients with schizophrenia, British Journal of Medical Economics, 7, 25–34.Google Scholar
May, P. R. A., Dencker, S. J., Hubbard, J. W., et al (1988) A systematic approach to treatment resistance in schizophrenic disorders. In Treatment Resistance in Schizophrenia (eds S. J. Dencker & F. Kulhanek), pp. 22–33. Viewig: Braunschweig.Google Scholar
Meltzer, H. Y. (1995) Clozapine: is another view valid? (Editorial). American Journal of Psychiatry, 152, 821–823.Google Scholar
Pacia, S. V. & Devinsky, O. (1994) Clozapine-related seizures: experience with 5629 patients. Neurology, 44, 2247–2249.Google Scholar
Reardon, G. T., Rifkin, A., Schwartz, A., et al (1989) Changing patterns of neuroleptic dosage over a decade. American Journal of Psychiatry, 146, 726–729.Google Scholar
Revicki, D. A., Luce, B. R., Weschler, J. M., et al (1990) Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hospital and Community Psychiatry, 41, 850–854.Google Scholar
Sassim, N. & Grohmann, R. (1988) Adverse drug reactions with clozapine and simultaneous application of benzodiazepines. Pharmacopsychiatry, 21, 306–307.CrossRefGoogle ScholarPubMed
Shalev, A., Hermesh, H., Rothberg, J., et al (1993) Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica, 87, 86–91.Google Scholar
Toth, P. & Frankenburg, F. R. (1994) Clozapine and seizures: a review. Canadian Journal of Psychiatry, 39, 236–238.Google Scholar
Viner, M. W., Escobar, J. I. & Werick, T. (1994) Clozapine plus psychoeducation in treatment refractory schizophrenia (Abstract). Neuropsychopharmacology, 10, S207.Google Scholar
Warner, J. P., Harvey, C. A. & Barnes, T. R. E. (1994) Clozapine and urinary incontinence. International Clinical Psychopharmacology, 9, 207–209.CrossRefGoogle ScholarPubMed
Welch, J., Manschrek, T. & Redmond, D. (1994) Clozapine-induced seizures and EEG changes. Journal of Neuropsychiatry and Clinical Neuroscience, 6, 250–256.Google ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.